動脈硬化治療薬市場：薬剤クラス別、投与経路別、病期別、流通チャネル別-2024～2030年の世界予測

動脈硬化治療薬市場規模は、2023年に225億9,000万米ドルと推定され、2024年には238億2,000万米ドルに達し、CAGR 5.66％で2030年には332億3,000万米ドルに達すると予測されています。

動脈硬化治療薬は、動脈硬化として知られる動脈内のプラークの蓄積を遅らせたり、元に戻したりするように設計された様々な薬剤を指します。この蓄積は、心臓病、脳卒中、その他の心血管系の問題を引き起こす可能性があります。これらの薬剤の使用拡大に寄与している主な要因としては、世界の心血管疾患の有病率の上昇、認知度と診断率の向上、薬剤開発の進歩、アテローム性動脈硬化症を発症するリスクの高い高齢化人口の増加などが挙げられます。しかしながら、これらの薬剤には、潜在的な副作用、個人によって異なる有効性、特に特許で保護された新しい薬剤では高額な治療費などの課題がないわけではありません。これらの問題に対処するためには、より効果的で安全な薬剤を開発し、医療費を削減する戦略を実施し、薬物療法を補完しうる生活習慣の改善に関する患者教育を改善するための継続的な研究が必要です。バイオテクノロジーの進歩や、個人の遺伝的体質に合わせた治療を行う個別化医療のアプローチは、動脈硬化治療薬の開発改善の機会を多様化させることが期待されます。

薬剤クラス別一般的なアテローム性動脈硬化症治療薬として、コレステロール低下薬の高い採用率

抗血小板剤は、血液中の血小板が凝集して血栓を形成するのを防ぐ薬剤です。血栓形成は動脈硬化における動脈狭窄の主な要因であり、心臓発作や脳卒中の原因となります。血小板凝集を阻害することにより、これらの薬剤はそのようなイベントのリスクを軽減します。降圧剤は、高血圧患者の血圧を下げるために使用される薬です。高血圧は動脈硬化とその合併症の重大な危険因子です。これらの薬剤は様々なメカニズムで血圧を下げ、心血管系の負担を軽減します。コレステロール低下薬は脂質低下薬としても知られ、主に血液中の脂質（脂肪）、特に動脈プラークの主要成分である低比重リポ蛋白（LDL）コレステロールのレベルを低下させる。LDLコレステロールを低下させることにより、動脈硬化の進行を抑制し、心血管イベントのリスクを低減します。

流通チャネルオンラインチャネルを通じた動脈硬化治療薬の入手可能性の向上

病院薬局は、特に臨床現場における動脈硬化症の急性期治療や管理において、主要な流通チャネルです。このチャネルは、病院の治療を受けている患者にとって必要な薬剤への即時アクセスを保証し、迅速な治療開始を促進します。小売薬局は、動脈硬化治療薬を一般の人々に直接配布するための重要なチャネルです。小売薬局は地理的に広い範囲をカバーしており、都市部と農村部の両方を含む広範な患者層に利用しやすい調剤を提供しています。小売薬局は、患者が実店舗を通じて処方箋に記入することを可能にし、動脈硬化を含む慢性疾患を病院の外で管理する上で極めて重要な役割を果たします。オンライン薬局は、デジタルヘルスプラットフォームの進歩により、急速に成長する流通チャネルとして出現しました。オンライン薬局は、患者がオンラインで医薬品を注文し、自宅の玄関先まで直接配送するという便利なオプションを提供しています。このチャネルは、移動に問題のある患者や遠隔地に住む患者にとって特に有利です。

地域別インサイト

南北アメリカは、強固な研究開発インフラ、多額のヘルスケア支出、大手製薬企業の強い存在感を背景に、動脈硬化治療薬の開発が盛んです。この地域は、先進的なヘルスケアのフレームワークと、医薬品のイノベーションと迅速な採用を促進する有利な政府政策から利益を得ています。一方、中国、日本、インドなどに代表されるAPAC地域では、動脈硬化治療薬市場が急成長しています。この急成長の背景には、ヘルスケアに対する意識の高まり、心血管疾患の有病率の上昇、ヘルスケアインフラの整備があります。しかし、APAC市場は国内外プレーヤーが混在し、より細分化されており、同地域ではコストに敏感なためジェネリック医薬品製造への注目が高まっています。一方、EMEAは規制基準が厳しく、医薬品の有効性と安全性が重視される成熟した市場です。欧州医薬品庁（EMA）の下で統一された欧州連合（EU）の規制枠組みは、加盟国間での医薬品承認プロセスの合理化を促進しているが、新規参入企業にとっては厳しい市場参入障壁となっています。EMEAの中東・アフリカセグメントは、市場規模こそ小さいもの、ヘルスケア・インフラへの投資の増加や慢性疾患管理への関心の高まりにより、徐々に拡大しています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは動脈硬化治療薬市場を評価する上で極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、動脈硬化治療薬市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4.競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力について徹底的な評価を行います。

5.製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1.動脈硬化治療薬市場の市場規模および予測は？

2.動脈硬化治療薬市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3.動脈硬化治療薬市場の技術動向と規制枠組みは？

4.動脈硬化治療薬市場における主要ベンダーの市場シェアは？

5.動脈硬化治療薬市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • CVDおよび動脈硬化性疾患の罹患率の増加
    • 心臓病の診断と早期治療を促進する取り組み
  • 抑制要因
    • 動脈硬化治療薬のリコールのリスク
  • 機会
    • 先進的な動脈硬化治療薬を導入するための進行中の調査プロジェクト
    • 動脈硬化治療薬に対する政府承認の増加
  • 課題
    • 動脈硬化の新薬開発の合併症
• 市場セグメンテーション分析
  • 薬物クラス：一般的な動脈硬化症の治療におけるコレステロール低下薬の採用率が高い
  • 配信チャネル：オンラインチャネルを通じて動脈硬化治療薬の入手性が向上しました
• 市場ディスラプション分析
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 価格分析
• 技術分析
• 特許分析
• 貿易分析
• 規制枠組みの分析

第6章 動脈硬化治療薬市場薬剤クラス別

• 降圧薬
• 抗血小板薬
• コレステロール低下薬

第7章 動脈硬化治療薬市場：投与経路別

• 注射可能
• オーラル

第8章 動脈硬化治療薬市場病気のステージ別

• アテローム形成
• アテローム性動脈硬化プラークの形成
• 脂肪縞の形成

第9章 動脈硬化治療薬市場：流通チャネル別

• 病院薬局
• オンライン薬局
• 小売薬局

第10章 南北アメリカの動脈硬化治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の動脈硬化治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの動脈硬化治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • NIH、テキサス心臓研究所に動脈硬化性心血管疾患の新薬開発のため114万米ドルを授与
  • 米国FDA、ノバルティスのレクビオ（インクリシラン）のLDLコレステロール値が高い成人への適応拡大を承認
  • 心血管疾患の抗炎症薬がFDAに承認
• 戦略分析と提言

第14章 競争力のあるポートフォリオ

• 主要企業プロファイル
• 主要製品ポートフォリオ

LIST OF FIGURES

• FIGURE 1. ATHEROSCLEROSIS DRUGS MARKET RESEARCH PROCESS
• FIGURE 2. ATHEROSCLEROSIS DRUGS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
• FIGURE 5. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. ATHEROSCLEROSIS DRUGS MARKET DYNAMICS
• FIGURE 7. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
• FIGURE 8. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 10. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2023 VS 2030 (%)
• FIGURE 12. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 13. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 14. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 15. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 16. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 17. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 18. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 19. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 20. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 23. ATHEROSCLEROSIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 24. ATHEROSCLEROSIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ATHEROSCLEROSIS DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, 2018-2023 (USD MILLION)
• TABLE 4. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, 2024-2030 (USD MILLION)
• TABLE 5. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 6. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 7. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 8. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 9. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ANTI-HYPERTENSIVE DRUGS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 10. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ANTI-HYPERTENSIVE DRUGS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 11. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 12. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 13. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CHOLESTEROL-LOWERING DRUGS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 14. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CHOLESTEROL-LOWERING DRUGS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 15. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 16. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 17. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 18. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 19. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2023 (USD MILLION)
• TABLE 20. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2024-2030 (USD MILLION)
• TABLE 21. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
• TABLE 22. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
• TABLE 23. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ATHEROMA FORMATION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 24. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ATHEROMA FORMATION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 25. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ATHEROSCLEROTIC PLAQUES FORMATION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 26. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ATHEROSCLEROTIC PLAQUES FORMATION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 27. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FATTY STREAKS FORMATION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 28. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FATTY STREAKS FORMATION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 29. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 30. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 31. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 32. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 33. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 34. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 35. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 36. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 37. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 38. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 39. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 40. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 41. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
• TABLE 42. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
• TABLE 43. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 44. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 45. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 46. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 47. ARGENTINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 48. ARGENTINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 49. ARGENTINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 50. ARGENTINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 51. ARGENTINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
• TABLE 52. ARGENTINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
• TABLE 53. ARGENTINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 54. ARGENTINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 55. BRAZIL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 56. BRAZIL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 57. BRAZIL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 58. BRAZIL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 59. BRAZIL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
• TABLE 60. BRAZIL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
• TABLE 61. BRAZIL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 62. BRAZIL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 63. CANADA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 64. CANADA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 65. CANADA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 66. CANADA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 67. CANADA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
• TABLE 68. CANADA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
• TABLE 69. CANADA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 70. CANADA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 71. MEXICO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 72. MEXICO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 73. MEXICO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 74. MEXICO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 75. MEXICO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
• TABLE 76. MEXICO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
• TABLE 77. MEXICO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 78. MEXICO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 79. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 80. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 81. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 82. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 83. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
• TABLE 84. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
• TABLE 85. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 86. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 87. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
• TABLE 88. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
• TABLE 89. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 90. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 91. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 92. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 93. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
• TABLE 94. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
• TABLE 95. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 96. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 97. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 98. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 99. AUSTRALIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 100. AUSTRALIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 101. AUSTRALIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 102. AUSTRALIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 103. AUSTRALIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
• TABLE 104. AUSTRALIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
• TABLE 105. AUSTRALIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 106. AUSTRALIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 107. CHINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 108. CHINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 109. CHINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 110. CHINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 111. CHINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
• TABLE 112. CHINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
• TABLE 113. CHINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 114. CHINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 115. INDIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 116. INDIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 117. INDIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 118. INDIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 119. INDIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
• TABLE 120. INDIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
• TABLE 121. INDIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 122. INDIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 123. INDONESIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 124. INDONESIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 125. INDONESIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 126. INDONESIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 127. INDONESIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
• TABLE 128. INDONESIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
• TABLE 129. INDONESIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 130. INDONESIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 131. JAPAN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 132. JAPAN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 133. JAPAN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 134. JAPAN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 135. JAPAN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
• TABLE 136. JAPAN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
• TABLE 137. JAPAN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 138. JAPAN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 139. MALAYSIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 140. MALAYSIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 141. MALAYSIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 142. MALAYSIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 143. MALAYSIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
• TABLE 144. MALAYSIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
• TABLE 145. MALAYSIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 146. MALAYSIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 147. PHILIPPINES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 148. PHILIPPINES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 149. PHILIPPINES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 150. PHILIPPINES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 151. PHILIPPINES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
• TABLE 152. PHILIPPINES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
• TABLE 153. PHILIPPINES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 154. PHILIPPINES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 155. SINGAPORE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 156. SINGAPORE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 157. SINGAPORE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 158. SINGAPORE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 159. SINGAPORE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
• TABLE 160. SINGAPORE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
• TABLE 161. SINGAPORE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 162. SINGAPORE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 163. SOUTH KOREA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 164. SOUTH KOREA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 165. SOUTH KOREA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 166. SOUTH KOREA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 167. SOUTH KOREA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
• TABLE 168. SOUTH KOREA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
• TABLE 169. SOUTH KOREA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 170. SOUTH KOREA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 171. TAIWAN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 172. TAIWAN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 173. TAIWAN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 174. TAIWAN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 175. TAIWAN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
• TABLE 176. TAIWAN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
• TABLE 177. TAIWAN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 178. TAIWAN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 179. THAILAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 180. THAILAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 181. THAILAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 182. THAILAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 183. THAILAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
• TABLE 184. THAILAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
• TABLE 185. THAILAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 186. THAILAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 187. VIETNAM ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 188. VIETNAM ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 189. VIETNAM ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 190. VIETNAM ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 191. VIETNAM ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
• TABLE 192. VIETNAM ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
• TABLE 193. VIETNAM ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 194. VIETNAM ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 195. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 196. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 197. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 198. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 199. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
• TABLE 200. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
• TABLE 201. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 202. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 203. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 204. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 205. DENMARK ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 206. DENMARK ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 207. DENMARK ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 208. DENMARK ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 209. DENMARK ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
• TABLE 210. DENMARK ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
• TABLE 211. DENMARK ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 212. DENMARK ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 213. EGYPT ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 214. EGYPT ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 215. EGYPT ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 216. EGYPT ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 217. EGYPT ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
• TABLE 218. EGYPT ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
• TABLE 219. EGYPT ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 220. EGYPT ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 221. FINLAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 222. FINLAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 223. FINLAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 224. FINLAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 225. FINLAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
• TABLE 226. FINLAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
• TABLE 227. FINLAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 228. FINLAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 229. FRANCE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 230. FRANCE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 231. FRANCE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 232. FRANCE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 233. FRANCE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
• TABLE 234. FRANCE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
• TABLE 235. FRANCE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 236. FRANCE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 237. GERMANY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 238. GERMANY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 239. GERMANY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 240. GERMANY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 241. GERMANY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
• TABLE 242. GERMANY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
• TABLE 243. GERMANY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 244. GERMANY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 245. ISRAEL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 246. ISRAEL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 247. ISRAEL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 248. ISRAEL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 249. ISRAEL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
• TABLE 250. ISRAEL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
• TABLE 251. ISRAEL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 252. ISRAEL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 253. ITALY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 254. ITALY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 255. ITALY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 256. ITALY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 257. ITALY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
• TABLE 258. ITALY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
• TABLE 259. ITALY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 260. ITALY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 261. NETHERLANDS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 262. NETHERLANDS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 263. NETHERLANDS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 264. NETHERLANDS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 265. NETHERLANDS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
• TABLE 266. NETHERLANDS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
• TABLE 267. NETHERLANDS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 268. NETHERLANDS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 269. NIGERIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 270. NIGERIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 271. NIGERIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 272. NIGERIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 273. NIGERIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
• TABLE 274. NIGERIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
• TABLE 275. NIGERIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 276. NIGERIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 277. NORWAY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 278. NORWAY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 279. NORWAY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 280. NORWAY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 281. NORWAY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
• TABLE 282. NORWAY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
• TABLE 283. NORWAY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 284. NORWAY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 285. POLAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 286. POLAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 287. POLAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 288. POLAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 289. POLAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
• TABLE 290. POLAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
• TABLE 291. POLAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 292. POLAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 293. QATAR ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 294. QATAR ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 295. QATAR ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 296. QATAR ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 297. QATAR ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
• TABLE 298. QATAR ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
• TABLE 299. QATAR ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 300. QATAR ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 301. RUSSIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 302. RUSSIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 303. RUSSIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 304. RUSSIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 305. RUSSIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
• TABLE 306. RUSSIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
• TABLE 307. RUSSIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 308. RUSSIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 309. SAUDI ARABIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 310. SAUDI ARABIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 311. SAUDI ARABIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 312. SAUDI ARABIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 313. SAUDI ARABIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
• TABLE 314. SAUDI ARABIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
• TABLE 315. SAUDI ARABIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 316. SAUDI ARABIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 317. SOUTH AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 318. SOUTH AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 319. SOUTH AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 320. SOUTH AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 321. SOUTH AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
• TABLE 322. SOUTH AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
• TABLE 323. SOUTH AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 324. SOUTH AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 325. SPAIN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 326. SPAIN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MIL

[188 Pages Report] The Atherosclerosis Drugs Market size was estimated at USD 22.59 billion in 2023 and expected to reach USD 23.82 billion in 2024, at a CAGR 5.66% to reach USD 33.23 billion by 2030.

Atherosclerosis drugs refer to a variety of medications designed to slow or reverse the buildup of plaque in the arteries, a condition known as atherosclerosis. This buildup can lead to heart disease, stroke, and other cardiovascular issues. The major factors contributing to the expansion of their use include the rising prevalence of cardiovascular diseases globally, increased awareness and diagnosis rates, advancements in drug development, and a growing aging population at higher risk of developing atherosclerosis. However, these drugs are not without their challenges, such as potential side effects, varying efficacy among individuals, and the high cost of treatment, particularly with newer, patent-protected medications. Addressing these issues requires ongoing research to develop more effective and safer medications, implement strategies to reduce healthcare costs, and improve patient education on lifestyle changes that can complement drug therapy. Biotechnology advancements and personalized medicine approach that tailor treatment to the individual's genetic makeup is expected to diversify the opportunities for the improved development of atherosclerosis drugs.

Drug Class: High adoption of cholesterol-lowering drugs for general atherosclerosis treatment

Antiplatelet agents are drugs that prevent blood platelets from clumping together to form clots. Clot formation is a major contributing factor in the narrowing of arteries in atherosclerosis, which can lead to heart attacks and strokes. By inhibiting platelet aggregation, these drugs reduce the risk of such events. Anti-hypertensive drugs are medications used to lower blood pressure in individuals with hypertension. High blood pressure is a significant risk factor for the development of atherosclerosis and its complications. These drugs work through various mechanisms to reduce blood pressure, reducing the cardiovascular system's strain. Cholesterol-lowering drugs, also known as lipid-lowering medications, primarily reduce levels of lipids (fats) in the blood, particularly low-density lipoprotein (LDL) cholesterol, which is a major component of arterial plaque. Lowering LDL cholesterol reduces the progression of atherosclerosis and the risk of cardiovascular events.

Distribution Channel: Improved availability of atherosclerosis drugs through online channels

Hospital pharmacies represent a primary distribution channel, particularly for acute treatment and management of atherosclerosis within a clinical setting. This channel ensures immediate access to necessary medications for patients under hospital care, facilitating prompt treatment initiation. Retail pharmacies serve as a critical channel for the distribution of atherosclerosis drugs directly to the public. They offer extensive geographical coverage, providing accessible medication dispensation to a broad patient demographic, including both urban and rural areas. Retail pharmacies enable patients to fill prescriptions through a physical storefront, which can be pivotal in managing chronic conditions, including atherosclerosis, outside of a hospital setting. Online pharmacies have emerged as a rapidly growing distribution channel owing to advances in digital health platforms. They offer a convenient option for patients to order their drugs online and have them delivered directly to their doorstep. This channel is particularly advantageous for individuals with mobility issues or those residing in remote areas.

Regional Insights

The Americas showcases significant atherosclerosis drug development, backed by robust R&D infrastructure, significant healthcare expenditure, and a strong presence of leading pharmaceutical companies. This region benefits from advanced healthcare frameworks and favorable government policies promoting drug innovation and quick adoption. Conversely, the APAC region, led by countries such as China, Japan, and India, is experiencing rapid growth in the atherosclerosis drugs market. This surge is powered by increasing healthcare awareness, rising cardiovascular disease prevalence, and improving healthcare infrastructures. However, APAC's market is more fragmented with a mix of local and international players, and there is a rising focus on generic drug production due to cost sensitivity in the region. On the other hand, EMEA presents a mature market scenario with stringent regulatory standards and a strong emphasis on drug efficacy and safety. The European Union's unified regulatory framework under the European Medicines Agency (EMA) facilitates a streamlined process for drug approval across member states yet poses challenging market entry barriers for new players. The Middle East and Africa segment of EMEA, while smaller in market size, is gradually expanding, owing to increasing investment in healthcare infrastructure and a growing focus on chronic disease management.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Atherosclerosis Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Atherosclerosis Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Atherosclerosis Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agepha Pharma US, Amgen Inc., Anthos Therapeutics, Artery Therapeutics, Inc., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, Cardurion Pharmaceuticals, CSL Behring, Eli Lilly and Company, Esperion Therapeutics, Inc., NewAmsterdam Pharma, Novartis AG, Novo Nordisk A/S, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi SA, Takeda Pharmaceutical Company Limited, and Verve Therapeutics.

Market Segmentation & Coverage

This research report categorizes the Atherosclerosis Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Drug Class
  • Anti-Hypertensive Drugs
  • Antiplatelet Agents
  • Cholesterol-lowering Drugs

• Route of Administration
  • Injectable
  • Oral

• Disease Stage
  • Atheroma Formation
  • Atherosclerotic Plaques Formation
  • Fatty Streaks Formation

• Distribution Channel
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam

• Europe, Middle East & Africa
  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Atherosclerosis Drugs Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Atherosclerosis Drugs Market?

3. What are the technology trends and regulatory frameworks in the Atherosclerosis Drugs Market?

4. What is the market share of the leading vendors in the Atherosclerosis Drugs Market?

5. Which modes and strategic moves are suitable for entering the Atherosclerosis Drugs Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of CVDs and atherosclerosis diseases
    • 5.1.1.2. Initiatives promoting diagnosis and early treatment of heart diseases
  • 5.1.2. Restraints
    • 5.1.2.1. Risk of recalls of atherosclerosis drugs
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing research projects for introducing advanced atherosclerosis drugs
    • 5.1.3.2. Rising government approvals for atherosclerosis drugs
  • 5.1.4. Challenges
    • 5.1.4.1. Complications of new atherosclerosis drug development
• 5.2. Market Segmentation Analysis
  • 5.2.1. Drug Class: High adoption of cholesterol-lowering drugs for general atherosclerosis treatment
  • 5.2.2. Distribution Channel: Improved availability of atherosclerosis drugs through online channels
• 5.3. Market Disruption Analysis
• 5.4. Porter's Five Forces Analysis
  • 5.4.1. Threat of New Entrants
  • 5.4.2. Threat of Substitutes
  • 5.4.3. Bargaining Power of Customers
  • 5.4.4. Bargaining Power of Suppliers
  • 5.4.5. Industry Rivalry
• 5.5. Value Chain & Critical Path Analysis
• 5.6. Pricing Analysis
• 5.7. Technology Analysis
• 5.8. Patent Analysis
• 5.9. Trade Analysis
• 5.10. Regulatory Framework Analysis

6. Atherosclerosis Drugs Market, by Drug Class

• 6.1. Introduction
• 6.2. Anti-Hypertensive Drugs
• 6.3. Antiplatelet Agents
• 6.4. Cholesterol-lowering Drugs

7. Atherosclerosis Drugs Market, by Route of Administration

• 7.1. Introduction
• 7.2. Injectable
• 7.3. Oral

8. Atherosclerosis Drugs Market, by Disease Stage

• 8.1. Introduction
• 8.2. Atheroma Formation
• 8.3. Atherosclerotic Plaques Formation
• 8.4. Fatty Streaks Formation

9. Atherosclerosis Drugs Market, by Distribution Channel

• 9.1. Introduction
• 9.2. Hospital Pharmacies
• 9.3. Online Pharmacies
• 9.4. Retail Pharmacies

10. Americas Atherosclerosis Drugs Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Atherosclerosis Drugs Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Atherosclerosis Drugs Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. NIH Awards The Texas Heart Institute USD 1.14 Million To Develop A Novel Drug For Atherosclerotic Cardiovascular Disease
  • 13.3.2. US FDA Approves Expanded Indication For Novartis Leqvio (inclisiran) For Adults With High LDL-C
  • 13.3.3. Anti-Inflammatory Drug for Cardiovascular Disease Approved by FDA
• 13.4. Strategy Analysis & Recommendation

14. Competitive Portfolio

• 14.1. Key Company Profiles
• 14.2. Key Product Portfolio